Latest Breaking News On - Dennis liotta - Page 5 : comparemela.com

The BIO Africa Digital Convention 2021 - The Mail & Guardian

Vaxart Announces Exclusive Worldwide License Agreement with

Opinion | In the Race for a Covid-19 Pill, a Little Lab Plays a Big Role

Mr. Adams is a journalist in Atlanta who has written about the pharmaceutical industry. ATLANTA Nine years ago, Dr. Dennis Liotta, a professor of organic chemistry at Emory University, set out to change the way drugs are developed for so-called neglected diseases those that primarily affect populations in poorer countries and for which there exist few, if any, safe and effective treatments. “The cold hard truth is that it can cost billions of dollars and take decades to develop a new drug,” he said during a TEDx talk in 2016, shortly after the World Health Organization had declared the Zika virus a neglected disease that had long been overlooked in the African countries where it is endemic an international public health emergency. “So pharmaceutical companies almost invariably only pursue drugs for diseases that will generate large profits.”

VIC Technology Venture Development Announces New Additions to Strategic Advisory Board, Bringing Together Industry Veterans to Guide Medical Innovation

VIC Technology Venture Development Announces New Additions to Strategic Advisory Board, Bringing Together Industry Veterans to Guide Medical Innovation Share Article Dr. Dennis Liotta and Dr. Paul Atkins “They are both innovative, life science veterans that have taken impactful technologies from the earliest stage to highly successful exits and we are fortunate to have them on our team.” said Calvin Goforth, Chief Executive Officer of VIC. FAYETTEVILLE, Ark. (PRWEB) May 17, 2021 VIC Technology Venture Development, which creates and develops high impact life science companies based on technologies exclusively licensed from top research institutions worldwide, announced today two new distinguished additions to their Strategic Advisory Board from across the life science industry.

Sameshnee Pelly, Ph.D. Patent Agent Finnegan, Henderson, Farabow, Garrett & Dunner

Legal Disclaimer You are responsible for reading, understanding and agreeing to the National Law Review s (NLR’s) and the National Law Forum LLC s  Terms of Use and Privacy Policy before using the National Law Review website. The National Law Review is a free to use, no-log in database of legal and business articles. The content and links on www.NatLawReview.com are intended for general information purposes only. Any legal analysis, legislative updates or other content and links should not be construed as legal or professional advice or a substitute for such advice. No attorney-client or confidential relationship is formed by the transmission of information between you and the National Law Review website or any of the law firms, attorneys or other professionals or organizations who include content on the National Law Review website. If you require legal or professional advice, kindly contact an attorney or other suitable professional advisor.